Experts are increasingly examining retatrutide, a novel drug created by Eli Lilly, as a possible advance in weight reduction . Different than many earlier approaches, retatrutide is a twin-action agonist targeting simultaneously GLP-1 and GIP, hormones that impact appetite and glucose regulation